

# Claims

b 1 1. A method of <sup>reducing</sup> ~~inhibiting~~ mammalian hair growth  
2 which comprises  
3 selecting an area of skin from which reduced hair  
4 growth is desired; and  
5 applying to said area of skin a dermatologically  
6 acceptable composition comprising a non-steroidal suppressor  
b 7 of angiogenesis in an amount effective to <sup>reduce</sup> ~~inhibit~~ hair  
8 growth.

1 2. The method of claim 1, wherein said suppressor  
2 is a compound that interferes with the action of heparin  
3 sulfate proteoglycans.

1 3. The method of claim 2, wherein said compound is  
2 an inhibitor of sulfotransferase.

1 4. The method of claim 2, wherein said compound is  
2 a heparin binding antagonist.

1 5. The method of claim 2, wherein said compound is  
2 a copper chelator.

1 6. The method of claim 1, wherein said suppressor  
2 is a compound that interferes with the action of histamine.

1 7. The method of claim 6, wherein said compound is  
2 an inhibitor of histidine decarboxylase.

E 8. The method of claim 6, wherein said compound is  
1 an inhibitor of mast cell degranulation.  
2


1           9. The method of claim 6, wherein said compound is  
2 a histamine receptor antagonist.

1           10. The method of claim 1, wherein said suppressor  
2 is a compound that interferes with the action of angiotensin  
3 II.

1           11. The method of claim 10, wherein said compound  
2 is an inhibitor of angiotensin converting enzyme.

1           12. The method of claim 10, wherein said compound  
2 is an angiotensin II receptor antagonist.

1           13. The method of claim 1, wherein said suppressor  
2 is a compound that interferes with the action of  
3 prostaglandin E1.

 1           14. The method of claim 1, wherein said compound is  
2 an inhibitor of prostaglandin synthetase.

1           15. The method of claim 1 wherein said suppressor  
2 interferes with the action of Substance P.

1           16. The method of claim 15, wherein said compound  
2 is an NK1 receptor antagonist.

1           17. The method of claim 1, wherein said suppressor  
2 interferes with the action of platelet activating factor.

1           18. The method of claim 17, wherein said compound  
2 is a platelet activating factor receptor antagonist.

1            19. The method of claim 1, wherein said suppressor  
2 interferes with the action of 12-HETrE.

1            20. The method of claim 19, wherein said compound  
2 is an inhibitor of cytochrome P450 reductase.

1            21. The method of claim 1, wherein said composition  
2 further comprises vehicle.

1            22. The method of claim 1, wherein the  
2 concentration of said suppressor in said composition is  
3 between 1% and 30% by weight.

1            23. The method of claim 1, wherein the composition  
2 provides a reduction in hair growth of at least 20% when  
3 tested in the Golden Syrian hamster assay.

1            24. The method of claim 1, wherein the composition  
2 provides a reduction in hair growth of at least 50% when  
3 tested in the Golden Syrian hamster assay.

1            25. The method of claim 1, wherein the composition  
2 provides a reduction in hair growth of at least 70% when  
3 tested in the Golden Syrian hamster assay.

1            26. The method of claim 1, wherein the suppressor  
2 is applied to the skin in an amount of from 100 to 3000  
3 micrograms of said inhibitor per square centimeter of skin.

1            27. The method of claim 1, wherein said mammal is a  
2 human.

27  
1 ~~28.~~ The method of claim 27, wherein said area of  
2 skin is on the face of the human.

28  
1 ~~29.~~ The method of claim 28, wherein said human is a  
2 woman suffering from hirsutism.

b 1 30. A method of <sup>reducing</sup> ~~inhibiting~~ mammalian hair growth  
2 which comprises  
3 selecting an area of skin from which reduced hair  
4 growth is desired; and  
5 applying to said area of skin a dermatologically  
6 acceptable composition comprising an inhibitor of  
7 sulfotransferase in an amount effective to <sup>reduce</sup> ~~inhibit~~ hair  
8 growth.

30  
1 ~~31.~~ The method of claim 30, wherein said inhibitor  
2 is p-nitrocatechol.

31  
1 ~~32.~~ The method of claim 30, wherein said inhibitor  
2 is catechin.

b 1 33. A method of <sup>reducing</sup> ~~inhibiting~~ mammalian hair growth  
2 which comprises  
3 selecting an area of skin from which reduced hair  
4 growth is desired; and  
5 applying to said area of skin a dermatologically  
6 acceptable composition comprising a heparin binding  
7 antagonist in an amount effective to <sup>reduce</sup> ~~inhibit~~ hair growth.

33  
1 ~~34.~~ The method of claim 33, wherein said antagonist  
2 is pentosan polysulfate.

1 <sup>34</sup>~~35~~. The method of claim <sup>32</sup>~~33~~, wherein said antagonist  
2 is quinacrine.

b 1 <sup>36</sup> 36. A method of <sup>reducing</sup>~~inhibiting~~ mammalian hair growth  
2 which comprises  
3 selecting an area of skin from which reduced hair  
4 growth is desired; and  
5 applying to said area of skin a dermatologically  
6 acceptable composition comprising a copper chelator in an  
7 amount effective to <sup>reduce</sup>~~inhibit~~ hair growth.

1 <sup>34</sup>~~37~~. The method of claim <sup>35</sup>~~36~~, wherein said copper  
2 chelator is bathocuproine disulfonate.

1 <sup>37</sup>~~38~~. The method of claim <sup>35</sup>~~36~~, wherein said copper  
2 chelator is diethylenetriamine pentaacetic acid.

b 1 <sup>39</sup> 39. A method of <sup>reducing</sup>~~inhibiting~~ mammalian hair growth  
2 which comprises  
3 selecting an area of skin from which reduced hair  
4 growth is desired; and  
5 applying to said area of skin a dermatologically  
6 acceptable composition comprising an inhibitor of histidine  
7 decarboxylase in an amount effective to <sup>reduce</sup>~~inhibit~~ hair growth.

1 <sup>39</sup>~~40~~. The method of claim <sup>38</sup>~~39~~, wherein said inhibitor  
2 is O-p-nitrohydroxylamine.

1 <sup>40</sup>~~41~~. The method of claim <sup>38</sup>~~39~~, wherein said inhibitor  
2 is  $\alpha$ -fluoromethylhistidine.

b 1 42. A method of <sup>reducing</sup> ~~inhibiting~~ mammalian hair growth  
2 which comprises  
3 selecting an area of skin from which reduced hair  
4 growth is desired; and  
5 applying to said area of skin a dermatologically  
6 acceptable composition comprising an inhibitor of mast cell  
7 degranulation in an amount effective to <sup>reduce</sup> ~~inhibit~~ hair growth.

1 <sup>42</sup> 43. The method of claim 42, wherein said inhibitor  
2 is mycophenolic acid.

1 <sup>43</sup> 44. The method of claim 42, wherein said inhibitor  
2 is bromocryptine.

1 <sup>44</sup> 45. The method of claim 42, wherein said inhibitor  
2 is cromoglycate.

b 1 46. A method of <sup>reducing</sup> ~~inhibiting~~ mammalian hair growth  
2 which comprises  
3 selecting an area of skin from which reduced hair  
4 growth is desired; and  
5 applying to said area of skin a dermatologically  
6 acceptable composition comprising a histamine receptor  
7 antagonist in an amount effective to <sup>reduce</sup> ~~inhibit~~ hair growth.

1 <sup>46</sup> 47. The method of claim 46, wherein said antagonist  
2 is terfenadine.

1 <sup>47</sup> 48. The method of claim 46, wherein said antagonist  
2 is tripeleennamine.

1 <sup>48</sup>~~49~~. The method of claim <sup>45</sup>~~46~~, wherein said antagonist  
2 is chlorpheniramine.

1 <sup>49</sup>~~50~~. The method of claim <sup>45</sup>~~46~~, wherein said antagonist  
2 is cimetidine.

b 1 <sup>51</sup>~~51~~. A method of <sup>reducing</sup>~~inhibiting~~ mammalian hair growth  
2 which comprises  
3 selecting an area of skin from which reduced hair  
4 growth is desired; and  
5 applying to said area of skin a dermatologically  
6 acceptable composition comprising an inhibitor of  
7 angiotensin converting enzyme in an amount effective to  
8 <sup>reduce</sup>~~inhibit~~ hair growth.

1 <sup>51</sup>~~52~~. The method of claim <sup>50</sup>~~51~~, wherein said inhibitor  
2 is enalapril.

1 <sup>52</sup>~~53~~. The method of claim <sup>50</sup>~~51~~, wherein said inhibitor  
2 is lisinopril.

b 1 <sup>54</sup>~~54~~. A method of <sup>reducing</sup>~~inhibiting~~ mammalian hair growth  
2 which comprises  
3 selecting an area of skin from which reduced hair  
4 growth is desired; and  
5 applying to said area of skin a dermatologically  
6 acceptable composition comprising an angiotensin II receptor  
7 antagonist in an amount effective to <sup>reduce</sup>~~inhibit~~ hair growth.

1 <sup>54</sup>~~55~~. The method of claim <sup>53</sup>~~54~~, wherein said antagonist  
2 is a 1,4- substituted indole.

- 1 <sup>55</sup>~~56~~. The method of claim <sup>53</sup>~~54~~, wherein said antagonist  
2 is a dihydropyridine derivative.
- 1 <sup>54</sup>~~57~~. The method of claim <sup>55</sup>~~56~~, wherein said antagonist  
2 is nifedipine.
- 1 <sup>57</sup>~~58~~. The method of claim <sup>53</sup>~~54~~, wherein said antagonist  
2 is a triazolinone derivative.
- 1 <sup>58</sup>~~59~~. The method of claim <sup>57</sup>~~58~~, wherein said  
2 triazolinane derivative has a side chain at the N<sup>4</sup> position.
- 3 <sup>59</sup>~~60~~. The method of claim <sup>53</sup>~~54~~, wherein said antagonist  
4 is a tetrahydroisoquinoline carboxylic acid.
- 5 <sup>60</sup>~~61~~. The method of claim <sup>53</sup>~~54~~, wherein said antagonist  
6 is an imidazopyridine derivative.
- 7 <sup>61</sup>~~62~~. The method of claim <sup>60</sup>~~61~~, wherein said  
8 imidazopyridine derivative is a tetrahydroimidazopyridine  
9 carboxylic acid analog.
- 10 <sup>62</sup>~~63~~. The method of claim <sup>53</sup>~~54~~, wherein said antagonist  
11 is Losantan.



b 1                   64. A method of <sup>reducing</sup> ~~inhibiting~~ mammalian hair growth  
2 which comprises  
3                   selecting an area of skin from which reduced hair  
4 growth is desired; and  
5                   applying to said area of skin a dermatologically  
6 acceptable composition comprising an inhibitor of  
7 prostaglandin synthetase in an amount effective to <sup>reduce</sup> ~~inhibit~~  
8 hair growth.

63  
64                   65. The method of claim 64, wherein said inhibitor  
is piracetam.

c 1                   66. A method of <sup>reducing</sup> ~~inhibiting~~ mammalian hair growth  
2 which comprises  
3                   selecting an area of skin from which reduced hair  
4 growth is desired; and  
5                   applying <sup>topically</sup> to said area of skin a dermatologically  
6 acceptable composition comprising an NK<sup>1</sup> receptor antagonist  
7 in an amount effective to <sup>reducing</sup> ~~inhibit~~ hair growth.

I 64  
65                   67. The method of claim 66, wherein said antagonist  
2 is (3aR,7aR)-7,7,-diphenyl-2-[1-imino-2-(2-methoxyphenyl)  
3 ethyl]perhydroisoindol-4-one.

67                   68. The method of claim 66, wherein said antagonist  
2 is cis-2-(diphenylmethyl)-N-[(2-methoxy-phenyl)]-methyl]-1-  
3 azabicyclo[2,2,2]octan-3-amine.

69. A method of <sup>reducing</sup> ~~inhibiting~~ mammalian hair growth which comprises selecting an area of skin from which reduced hair growth is desired; and applying to said area of skin a dermatologically acceptable composition comprising a platelet activating factor receptor antagonist in an amount effective to <sup>reduce</sup> ~~inhibit~~ hair growth.

70. The method of claim 69, wherein said antagonist is tioconazole.

71. The method of claim 69, wherein said antagonist is (3-[4-(2-chlorophenyl)-9-methyl-6H-thieno[2-f]-[1,2,4]triazolo-[4,3-a][1,4]-diazepin-2-yl-1-(4-morpholinyl)-1-propanone.

72. A method of <sup>reducing</sup> ~~inhibiting~~ mammalian hair growth which comprises selecting an area of skin from which reduced hair growth is desired; and applying to said area of skin a dermatologically acceptable composition comprising an inhibitor of cytochrome P450 reductase in an amount effective to <sup>reduce</sup> ~~inhibit~~ hair growth.

73. The method of claim 72, wherein said inhibitor is clotrimazole.

b

1                    74. A method of <sup>reducing</sup> ~~inhibiting~~ mammalian hair growth  
2 which comprises  
3                    selecting an area of skin from which reduced hair  
4 growth is desired; and  
5                    applying to said area of skin a dermatologically  
6 acceptable composition comprising, in an amount effective to  
7 reduce hair growth, a compound selected from the group  
8 consisting of phenyl-ethylene derivatives such as tamoxifen  
9 and nafoxidine; irsogladine; the synthetic laminin peptide,  
10 CDPGYIGSR-NH<sub>2</sub>; radicicol; eponemycin; fumagillin (O-  
11 (chloroacetyl-carbamoyl)fumagillol) and synthetic analoges  
12 thereof; recombinant human platelet factor-4 and related  
13 peptides; protamine; sulfated chitin derivatives;  
14 diaminoanthraquinone derivatives; thrombospondin; quinoline-  
15 3-carboxamide (linomide); analogues of diatamycin A; and  
16 aurintricarboxylic acid.

5/2/86

ADD 6/5

add H4

add F4